<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; big</title>
	<atom:link href="http://www.tapanray.in/tag/big/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovation: Is Big Pharma Talking Differently?</title>
		<link>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovation-is-big-pharma-talking-differently</link>
		<comments>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/#comments</comments>
		<pubDate>Mon, 17 Sep 2018 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[differently]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Egypt]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmasset]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9139</guid>
		<description><![CDATA[“Nearly 2 billion people have no access to basic medicines, causing a cascade of preventable misery and suffering. Good health is impossible without access to pharmaceutical products.” The World Health Organization’s (WHO) ‘Access to Medicine’ report on ‘Ten years in &#8230; <a href="http://www.tapanray.in/innovation-is-big-pharma-talking-differently/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovation-is-big-pharma-talking-differently/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Core Purpose of Pharma Business Much Beyond Profit Making?</title>
		<link>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-core-purpose-of-pharma-business-much-beyond-profit-making</link>
		<comments>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/#comments</comments>
		<pubDate>Mon, 10 Nov 2014 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carmakers]]></category>
		<category><![CDATA[Chan]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[expenditure. India]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[margins]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Oil&gas]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pupose]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[West]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6164</guid>
		<description><![CDATA[Dr. Margaret Chan, the Director General of the World Health Organization (WHO), at a briefing to discuss the Ebola outbreak in West Africa at the UN Foundation in Washington on September 3, 2014 said: “Big Pharma&#8217;s greed for profits, not &#8230; <a href="http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma’s Windfall Gain From Indian Pharma’s Loss, Costs American Patients Dear</title>
		<link>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear</link>
		<comments>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/#comments</comments>
		<pubDate>Thu, 19 Jun 2014 09:23:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UDFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5540</guid>
		<description><![CDATA[According to US-FDA, its ‘Import Bans’ on quality grounds of the drugs manufactured at various Indian facilities, such as, Ranbaxy’s Paonta Sahib, Dewas and Mohali and Toansa plants, were reportedly solely directed at negating the health safety risks of American patients &#8230; <a href="http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharmas-windfall-gain-from-indian-pharmas-loss-costs-american-patients-dear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Receives Another Body Blow: Would Indian Slumber End Now?</title>
		<link>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-receives-another-body-blow-would-indian-slumber-end-now</link>
		<comments>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/#comments</comments>
		<pubDate>Mon, 19 May 2014 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blow]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[Heptodin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Mark]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[receives]]></category>
		<category><![CDATA[Reily]]></category>
		<category><![CDATA[rip-off]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[slumber]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Wake-up]]></category>
		<category><![CDATA[Xinhua]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5407</guid>
		<description><![CDATA[On May 13, 2014, The New York Times reported, while major pharmaceutical companies have been facing increased scrutiny of their marketing practices from governments around the world, last Wednesday the Chinese authorities sent a strong warning to the pharmaceutical industry &#8230; <a href="http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global New Product Launches: Recent Success Trend Unflattering?</title>
		<link>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-new-product-launches-recent-success-trend-unflattering</link>
		<comments>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/#comments</comments>
		<pubDate>Mon, 24 Mar 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[2006]]></category>
		<category><![CDATA[2007]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[FirstWord]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[McKinsey]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[unflattering]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5132</guid>
		<description><![CDATA[New products are the lifeblood for any company, including the pharmaceutical players. Business performance and sustainable growth of the pharmaceutical industry, as a whole depend on quality of R&#38;D output in terms of &#8216;New Molecules&#8217;, followed by successful development and &#8230; <a href="http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-new-product-launches-recent-success-trend-unflattering/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Loss of Ranbaxy, Gain of Big Pharma…And Two Intriguing Coincidences</title>
		<link>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences</link>
		<comments>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/#comments</comments>
		<pubDate>Mon, 17 Mar 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[coincidences]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[double]]></category>
		<category><![CDATA[gain]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hypothesis]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[Machiavellian]]></category>
		<category><![CDATA[murkier]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whammy]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5096</guid>
		<description><![CDATA[In March 2014, the largest pharma player of India by market capitalization, Sun Pharma, became the latest of the large Indian pharma exporters facing the US-FDA ‘Import Ban’ for drugs manufactured at its Gujarat-based plant. This news came as a &#8230; <a href="http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/loss-of-ranbaxy-gain-of-big-pharmaand-two-intriguing-coincidences/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Credibility Erosion of Pharma Accelerating?</title>
		<link>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-credibility-erosion-of-pharma-accelerating</link>
		<comments>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/#comments</comments>
		<pubDate>Mon, 10 Mar 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5060</guid>
		<description><![CDATA[‘Big Pharma’ now seems to be desperately trying to gain the long lost high moral ground by pushing  hard its gigantic image makeover juggernaut, maintaining a strong pitch on the relevance of stringent Intellectual Property Rights (IPR) in the lives &#8230; <a href="http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
